Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First case of A859T epidermal growth factor receptor mutation responding to erlotinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2011

Le Maignan Laureline, Mirebeau-Prunier Delphine, Vervueren Laurent, Jeanfaivre Thierry, Urban Thierry, Hureaux José

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adrenal Gland Neoplasms
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Positron-Emission Tomography

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 21317745
DOI: 10.1097/JTO.0b013e3182037c0c

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First case of A859T epidermal growth factor receptor mutation responding to erlotinib.PMID 21317745Read ↗

First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation.Semantic proximity Read ↗

Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.Semantic proximity Read ↗

Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases.Semantic proximity Read ↗

Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.Semantic proximity Read ↗

A lung adenocarcinoma with rare epidermal growth factor receptor exon 20 V774M mutation was sensitive to osimertinib: A case report and molecular structural analysis.Semantic proximity Read ↗

Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.Semantic proximity Read ↗

Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.Semantic proximity Read ↗

An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report.Semantic proximity Read ↗

Are 19del and L858R really different disease entities?Semantic proximity Read ↗

A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib.Semantic proximity Read ↗

Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non-Small Cell Lung Cancer Patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.